Effects of Clopidogrel and Itraconazole on the Disposition of Efavirenz and Its Hydroxyl Metabolites: Exploration of a Novel CYP2B6 Phenotyping Index

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2012 May 5

PMID 22554354

Citations 12

Authors

Fen Jiang

Zeruesenay Desta

Ji-Hong Shon

Chang-Woo Yeo

Ho-Sook Kim

Kwang-Hyeon Liu

Soo-Kyung Bae

Sang-Seop Lee

David A Flockhart

Jae-Gook Shin

Affiliations

Soon will be listed here.

Abstract

Aims: To evaluate the effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites in relation to the CYP2B6*6 genotype and explore potential phenotyping indices for CYP2B6 activity in vivo using a low dose of oral efavirenz.

Methods: We conducted a randomized three phase crossover study in 17 healthy Korean subjects pre-genotyped for the CYP2B6*6 allele (CYP2B6*1/*1, n = 6; *1/*6, n = 6; *6/*6, n = 5). Subjects were pretreated with clopidogrel (75 mg day(-1) for 4 days), itraconazole (200 mg day(-1) for 6 days), or placebo and then given a single dose of efavirenz (200 mg). The plasma (0-120 h) and urine (0-24 h) concentrations of efavirenz and its metabolites (7- and 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz) were determined by LC/MS/MS.

Results: This study is the first to delineate quantitatively the full (phase I and II) metabolic profile of efavirenz and its three hydroxyl metabolites in humans. Clopidogrel pretreatment markedly decreased AUC(0,48 h), C(max) and Ae(0,24 h) for 8,14-dihydroxyefavirenz, compared with placebo; 95% CI of the ratios were 0.55, 0.73, 0.30, 0.45 and 0.25, 0.47, respectively. The 8,14-dihydroxyefavirenz : efavirenz AUC(0,120 h) ratio was significantly correlated with the weight-adjusted CL/F of efavirenz (r(2) ≈ 0.4, P < 0.05), differed with CYP2B6*6 genotype and was affected by clopidogrel pretreatment (P < 0.05) but not by itraconazole pretreatment.

Conclusions: The disposition of 8,14-dihydroxy-EFV appears to be sensitive to CYP2B6 activity alterations in human subjects. The 8,14-dihydroxyefaviremz : efavirenz AUC(0,120 h) ratio is attractive as a candidate phenotyping index for CYP2B6 activity in vivo.

Citing Articles

Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know.

De Bellis E, Donnarumma D, Zarrella A, Mazzeo S, Pagano A, Manzo V Pharmaceutics. 2025; 17(1).

PMID: 39861680 PMC: 11768951. DOI: 10.3390/pharmaceutics17010031.

Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction.

Di Paolo V, Ferrari F, Poggesi I, Quintieri L Clin Pharmacokinet. 2022; 61(9):1297-1306.

PMID: 35857278 DOI: 10.1007/s40262-022-01153-y.

Sources of Interindividual Variability.

Lin Y, Thummel K, Thompson B, Totah R, Cho C Methods Mol Biol. 2021; 2342:481-550.

PMID: 34272705 DOI: 10.1007/978-1-0716-1554-6_17.

Therapeutic activities of naringenin on efavirenz-induced sleep-like disorder in the midbrain of white albino mice.

Olufunke D, Edidiong A, Oluwatomisin F, Alani A Iran J Basic Med Sci. 2020; 23(11):1462-1470.

PMID: 33235704 PMC: 7671428. DOI: 10.22038/ijbms.2020.47043.10852.

Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs.

Burgess K, Ipe J, Swart M, Metzger I, Lu J, Gufford B Clin Pharmacol Ther. 2017; 104(1):130-138.

PMID: 28960269 PMC: 5871545. DOI: 10.1002/cpt.892.

References

Rohrbacher M, Kirchhof A, Geisslinger G, Lotsch J . Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics. 2006; 7(7):995-1002. DOI: 10.2217/14622416.7.7.995. View

Kharasch E, Mitchell D, Coles R . Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol. 2008; 48(4):464-74. DOI: 10.1177/0091270008314254. View

Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K . Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007; 8(6):547-58. DOI: 10.2217/14622416.8.6.547. View

Xu C, Ogburn E, Guo Y, Desta Z . Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos. 2012; 40(4):717-25. PMC: 3310426. DOI: 10.1124/dmd.111.042416. View

Mo S, Liu Y, Duan W, Wei M, Kanwar J, Zhou S . Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab. 2009; 10(7):730-53. DOI: 10.2174/138920009789895534. View

Richter T, Murdter T, Heinkele G, Pleiss J, Tatzel S, Schwab M . Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther. 2003; 308(1):189-97. DOI: 10.1124/jpet.103.056127. View

Mutlib A, Chen H, Nemeth G, Markwalder J, Seitz S, Gan L . Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos. 1999; 27(11):1319-33. View

Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K . Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005; 77(6):553-9. DOI: 10.1016/j.clpt.2005.02.010. View

Ogburn E, Jones D, Masters A, Xu C, Guo Y, Desta Z . Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos. 2010; 38(7):1218-29. PMC: 2908985. DOI: 10.1124/dmd.109.031393. View

10.

Hesse L, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke L . Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics. 2004; 14(4):225-38. DOI: 10.1097/00008571-200404000-00002. View

11.

Tucker G, Houston J, Huang S . Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. Br J Clin Pharmacol. 2001; 52(1):107-17. PMC: 2014497. DOI: 10.1046/j.0306-5251.2001.temp.1441.x. View

12.

Burger D, van der Heiden I, Porte C, van der Ende M, Groeneveld P, Richter C . Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006; 61(2):148-54. PMC: 1885008. DOI: 10.1111/j.1365-2125.2005.02536.x. View

13.

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K, Suda A . Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther. 2011; 90(3):406-13. DOI: 10.1038/clpt.2011.129. View

14.

Mehlotra R, Ziats M, Bockarie M, Zimmerman P . Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006; 62(4):267-75. PMC: 4450653. DOI: 10.1007/s00228-005-0092-9. View

15.

Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger U, Murdter T . Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003; 13(10):619-26. DOI: 10.1097/00008571-200310000-00005. View

16.

Lang T, Klein K, Fischer J, Nussler A, Neuhaus P, Hofmann U . Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001; 11(5):399-415. DOI: 10.1097/00008571-200107000-00004. View

17.

Bae S, Jeong Y, Lee C, Liu K . Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica. 2011; 41(6):437-44. DOI: 10.3109/00498254.2011.551849. View

18.

Ekins S, Wrighton S . The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev. 1999; 31(3):719-54. DOI: 10.1081/dmr-100101942. View

19.

Cho J, Lim H, Chung J, Yu K, Kim J, Shin S . Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos. 2004; 32(12):1341-4. DOI: 10.1124/dmd.104.001107. View

20.

Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel K, Ueda N . Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother. 2011; 66(10):2350-61. DOI: 10.1093/jac/dkr304. View